On April 7, 2026 Pluristyx, a leader in advanced induced pluripotent stem cell (iPSC)-based solutions, reported expansion of its intellectual property portfolio with a U.S. patent allowance for claims covering cells expressing autoimmune-associated self-antigens coupled with its exclusive induced Allogeneic Cell Tolerance (iACT Stealth) technology for "cell cloaking".
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The newly allowed patent claims are specifically drawn to the use of iACT in the treatment of autoimmune diseases. With this technology Pluristyx can combine a genetic engineering package integrating iACT Stealth with self-antigen technology, and "train" a patient’s own immune system. This innovative approach allows for a precise, desired immune response to a self-antigen without dangerous "off-target" effects or using traditional debilitating systemic immune suppression.
This patent marks a pivotal shift in the use of cell therapy beyond oncology. By pairing iACT Stealth cloaking with specific self-antigens, Pluristyx is enabling development of "tolerogenic" cell therapies. Unlike traditional methods that broadly suppress the immune system, leaving patients vulnerable to infections, this technology allows engineered cells to persist in the body and specifically retrain the immune system to stop attacking itself. This represents a new frontier in "living medicine," where engineered iPSC-derived cells act as a localized, intelligent platform for long-term autoimmune remission.
iACT Stealth is designed to work in tandem with Pluristyx’s FailSafe technology. FailSafe’s drug-inducible safety feature acts as a genetic "kill switch," allowing for the selective removal of any proliferating cells to ensure patient safety and is the only commercially-available safety switch technology.
"This addition to our patent portfolio furthers our commitment to advancing regenerative, living-medicine therapies, now in the autoimmune field," said Kaye Reiter, PhD, JD, Pluristyx Chief Legal Officer. "We continue to expand our exclusive intellectual property portfolio of combined iPSC, FailSafe, and iACT Stealth technologies that are setting the standard for functionality, safety, and scalability".
Pluristyx’s full suite of technologies, including iACT Stealth, FailSafe, and proprietary mRNA-based iPSC reprogramming technology, is available for immediate adoption through a streamlined research evaluation and commercial licensing model. This provides partners today with a powerful, clinical-grade foundation to bring tomorrow’s next-generation living medicines to market.
(Press release, Pluristyx, APR 7, 2026, View Source [SID1234664225])